Melanotan II vs PT-141
Same melanocortin mechanism, opposite regulatory standing: bremelanotide cleared phase 3 for one narrow indication, while Melanotan II never entered that system at all.
Short answer
Only PT-141 is FDA-approved; Melanotan II is not. PT-141 fits a reader who wants an FDA-approved product, though that approval does not cover every use it is marketed for, while Melanotan II is marketed for tanning and libido. On the evidence, Melanotan II has human clinical data and PT-141 has approval-level evidence.
Melanotan II
MT-2
Genuinely tans skin via MC1R, but it's an unapproved gray-market injectable with a documented harm record (priapism, changing moles) — and it is not the approved drug afamelanotide.
Full Melanotan II evidence reviewPT-141
Bremelanotide / Vyleesi
FDA-approved as Vyleesi for HSDD in premenopausal women, with phase-3 evidence — but the off-label use in men and at higher doses goes beyond what's proven.
Full PT-141 evidence reviewMelanotan II vs PT-141: head to head
- FDA status / approved use
Melanotan II
Not approved by the FDA or any major regulator; sold as gray-market injectable powderPT-141
FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women only- Marketed for
Melanotan II
Tanning, libidoPT-141
Libido, sexual dysfunction- Outcome areas
Melanotan II
Skin / hair; Sexual health / libidoPT-141
Sexual health / libido- Evidence grade
Melanotan II
Clinical dataPT-141
FDA-approved- How it works
Melanotan II
Activates the melanocortin-1 receptor on pigment cells, driving melanin productionPT-141
Activates melanocortin receptors in the brain involved in sexual desire- Route and dosing
Melanotan II
Self-injected after reconstituting a powder; no standard dosePT-141
On-demand subcutaneous injection before sexual activity, not daily- Headline human result
Melanotan II
Not establishedPT-141
Desire rose 0.35 points and distress fell 0.33 points vs placebo in the phase 3 RECONNECT trials of 1,267 women- Strongest evidence
Melanotan II
Habbema, Int J Dermatol 2017Melanotan II evidence reviewPubMed 28266027PT-141
RECONNECT phase 3, Obstet Gynecol 2019PT-141 evidence reviewPubMed 31599840- Key safety signal
Melanotan II
New and darkening moles; also nausea, flushing, blood pressure effects and priapismPT-141
Nausea is common; transient blood-pressure rise; possible lasting skin darkening- How it is obtained
Melanotan II
Sold gray-market as a research chemical; no approved or legitimately compounded human productPT-141
Prescribed and dispensed by compounding pharmacies; legality varies by compound
| Melanotan II | PT-141 | |
|---|---|---|
| FDA status / approved use | Not approved by the FDA or any major regulator; sold as gray-market injectable powder | FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women only |
| Marketed for | Tanning, libido | Libido, sexual dysfunction |
| Outcome areas | Skin / hair; Sexual health / libido | Sexual health / libido |
| Evidence grade | Clinical data | FDA-approved |
| How it works | Activates the melanocortin-1 receptor on pigment cells, driving melanin production | Activates melanocortin receptors in the brain involved in sexual desire |
| Route and dosing | Self-injected after reconstituting a powder; no standard dose | On-demand subcutaneous injection before sexual activity, not daily |
| Headline human result | Not established | Desire rose 0.35 points and distress fell 0.33 points vs placebo in the phase 3 RECONNECT trials of 1,267 women |
| Strongest evidence | Habbema, Int J Dermatol 2017Melanotan II evidence reviewPubMed 28266027 | RECONNECT phase 3, Obstet Gynecol 2019PT-141 evidence reviewPubMed 31599840 |
| Key safety signal | New and darkening moles; also nausea, flushing, blood pressure effects and priapism | Nausea is common; transient blood-pressure rise; possible lasting skin darkening |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Prescribed and dispensed by compounding pharmacies; legality varies by compound |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- FDA-approved:
- Approved by the FDA for a defined indication, on the strength of pivotal human trials.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
Bremelanotide is the active metabolite of Melanotan II, which is why they share effects such as nausea, flushing, and pigmentation changes, but the resemblance ends there. PT-141 is FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women, with replicated placebo-controlled evidence and a label built around its transient blood-pressure rise. Melanotan II has no approval anywhere, is sold as unregulated injectable powder, and carries a documented harm record: nausea and flushing, blood-pressure and cardiovascular effects, priapism, new and darkening moles that complicate melanoma surveillance, and rare severe events including renal infarction and posterior reversible encephalopathy syndrome. It is also not afamelanotide, the approved melanocortin drug it is often confused with.
Melanotan II fits if
Melanotan II is worth understanding mainly so you can recognize its documented risks and the common false claim that it is basically an approved drug.
PT-141 fits if
PT-141 is the appropriate one to look into only inside its approved indication and under supervision, given the blood-pressure effect.
Melanotan II vs PT-141: common questions
- Is PT-141 FDA-approved but Melanotan II not?
- Yes. PT-141 is FDA-approved as Vyleesi for acquired, generalized HSDD in premenopausal women only. Melanotan II is not approved by the FDA or any major regulator; sold as gray-market injectable powder.
- Which has stronger human evidence, Melanotan II or PT-141?
- PT-141. It has approval-level evidence (key source: RECONNECT phase 3, Obstet Gynecol 2019), while Melanotan II has human clinical data (key source: Habbema, Int J Dermatol 2017).
- What are the main safety concerns with Melanotan II and PT-141?
- For Melanotan II, watch for new and darkening moles; also nausea, flushing, blood pressure effects and priapism. With PT-141, nausea is common; transient blood-pressure rise; possible lasting skin darkening.
Key studies behind each
Melanotan II
- Habbema L, Halk AB, Neumann M, Bergman W. (2017). Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. PubMed 28266027
- Langan EA, Ramlogan D, Jamieson LA, Rhodes LE. (2009). Change in moles linked to use of unlicensed "sun tan jab". BMJ. PubMed 19174439
- Schulze F, Erdmann H, Hardkop LH, Schmidt-Naumann A. (2014). Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II. Eur J Dermatol. PubMed 24334249
- Devlin J, Pomerleau A, Foote J, et al. (2013). Melanotan II overdose associated with priapism. Clin Toxicol (Phila). PubMed 23537392
PT-141
- Kingsberg SA, Clayton AH, Portman D, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. PubMed 31599840
- Yuan XC, Tao YX. (2022). Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin. Biomolecules. PubMed 36291616
- Simon JA, Kingsberg SA, Portman D, et al. (2019). Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. PubMed 31599847
- Spielmans GI. (2021). Re-Analyzing Phase III Bremelanotide Trials for “Hypoactive Sexual Desire Disorder” in Women. J Sex Res. PubMed 33678061
The full evidence reviews
- Melanotan II (MT-2): a real skin-darkening drug with real, unapproved risks
MT-2 genuinely tans skin via the melanocortin-1 receptor — but it’s an unapproved gray-market injectable with a documented harm record, from priapism to changing moles. And it’s not the approved drug afamelanotide.
Updated August 2026
- PT-141 (bremelanotide): the evidence on a peptide that is actually FDA-approved
Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women, with phase-3 trial evidence. A straight read of what's proven — and where off-label use goes beyond it.
Updated August 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm Melanotan II availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: Clinic SecretContour HealthDadVantage Men's HealthDr. Gillis' Wellness CenterDrBrainRxElara MD